Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<p>Expansion of immune cells within tumors is, in part, due to CAN-2409 + prodrug–mediated stimulation of proliferation of T-cell subsets in the TME (total, neoantigen-specific, and stem-like CD8<sup>+</sup> T cells). <b>A,</b> The effect of CAN-2409 + prodrug treatment on proliferative status of T-cell subsets was assessed using Ki67 as a marker. Representative flow cytometry plots for total, KG<sup>+</sup>, and KR<sup>+</sup> populations of total, TAA–specific (MC38 pentamer<sup>+</sup>), and stem-like (PD-1<sup>+</sup>Ly108<sup>+</sup>) CD8<sup>+</sup> T cells and quantification are shown in <b>B–D</b>. <i>N</i> = 4–6 mice per group. Two-tailed <i>t</i> test, *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p>

Original publication

DOI

10.1158/2767-9764.28427839

Type

Publication Date

17/02/2025